IperionX Shares Gain Into Month End as Bullish Coverage Implies Significant Upside

IperionX shares (ASX:IPX) are in focus on both sides of the Pacific after a prominent U.S. investment bank initiated coverage with a bullish outlook, signalling growing institutional confidence in the company’s domestic titanium ambitions.

ASX Listed IperionX shares closed 5.71% higher at A$4.07, while the Nasdaq-listed American Depositary Receipts settled at US$26.94. The dual-listed advanced materials company has now recovered some ground after a volatile year that continues to see the share price down 29.71% year-to-date through the first half of 2026.

Today’s gains come as Texas Capital Securities initiated coverage with a Buy rating and a US$55 price target, implying more than 100% upside from current Nasdaq levels. With the ADR representing 10 ASX ordinary shares, the Texas Capital target translates to approximately US$5.50 per ASX share, or roughly A$7.85 to A$8.35 depending on foreign exchange assumptions, nearly double today’s closing price.

A Street View

Texas Capital’s initiation marks the latest in a string of positive coverage for IperionX shares. The firm characterised the company as a critical materials and technology business working to establish an end-to-end titanium supply chain within the United States, leveraging proprietary powder metallurgy and component technologies.

The analyst note emphasised IperionX’s vertical integration strategy, from raw material sourcing through titanium powder production to finished aerospace and defence components, as well as its potentially lower energy intensity and shorter lead times compared to legacy Kroll-process titanium routes. Texas Capital also highlighted the company’s strong balance sheet, noting cash exceeds debt and a current ratio above four, providing a financial cushion as the business scales.

Price Targets

The US$55 price target was derived from a discounted cash flow analysis of IperionX’s Titanium Manufacturing Campus in Virginia, combined with a net asset valuation of the Titan Critical Minerals Project. This methodology mirrors approaches taken by other covering analysts, including BTIG, which recently raised its target from US$40 to US$55, and Roth Capital, which holds a US$75 target.

Alliance Global Partners trimmed its target slightly from US$60 to US$53 but maintained a Buy rating, citing continued belief in the long-term thesis despite near-term volatility.

Strategic Foundations and Government Support

IperionX’s appeal to analysts rests on several strategic pillars. The company has outlined plans to accelerate its U.S. titanium build-out, targeting large-scale, low-cost titanium powder production through patented processing technologies. Management has indicated it aims to achieve titanium powder costs near US$55 per kilogram at scale, down from earlier estimates around US$75 per kilogram, a potential structural cost advantage versus conventional Kroll-based suppliers. This cost leadership, if realised, would position IperionX favourably in aerospace, defence, and additive manufacturing markets where titanium demand is expected to grow.

Crucially, the company has secured backing from U.S. government and Department of Defense programmes, with tens of millions of dollars in obligated federal funding directed toward its facilities. The U.S. Army has validated IperionX titanium parts, an important milestone in defence qualification processes.

These endorsements lend credibility to the company’s narrative as a strategic domestic supplier aligned with Washington’s push to reshore critical supply chains and reduce reliance on foreign titanium sources. IperionX has also emphasised environmental benefits, including recycling scrap titanium and lowering emissions relative to traditional production methods, themes that resonate with policymakers and sustainability-focused markets.

Early-Stage Realities and Insider Confidence

Despite the optimistic analyst outlook, IperionX remains in a relatively early commercial stage, a point Texas Capital explicitly acknowledged in its note.

The company reported a US$34.8 million loss with effectively zero revenue in its most recent financial disclosure, underscoring that it is still pre-profit and heavily reliant on capital markets and government grants to fund its expansion. This financial profile contributed to the sharp share price drawdown earlier this year, as markets re-rated execution and financing risk.

However, management has signalled confidence in the company’s trajectory. On 27 March 2026, four IperionX insiders collectively purchased over US$2.1 million of stock in the open market, including two first-time buyers. The insider buying episode, coming at depressed prices, was interpreted by some market observers as a strong vote of confidence in the long-term story.

Combined with the robust balance sheet and ongoing government funding, the transactions helped support the argument that IperionX is adequately funded through key near-term milestones, though the company has previously tapped equity markets via ASX placements, illustrating ongoing dilution risk as it funds its ambitious build-out.

What Lay Ahead

For ASX holders, the Texas Capital initiation and the broader analyst consensus suggest substantial upside potential, or roughly a doubling of value over the next 12 months if IperionX hits its milestones. The translation from Nasdaq to ASX is relatively straightforward given the ADR structure, and today’s 5% rally reflects the market’s willingness to re-rate the stock on positive analyst commentary.

Yet the story remains high-beta and execution-heavy. The same leverage that delivers outsized gains if the U.S. titanium build-out succeeds will magnify losses if contracts, plant ramp-up, or funding fall short. Key risks include the company’s continued losses, minimal near-term revenue, potential for further equity dilution, and the inherent uncertainty in scaling novel production technologies.